Lists of people executed in the United States

DGAP-News: The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October 13 and 14, 2022 in Paris

Retrieved on: 
Tuesday, September 6, 2022
Lists of people executed in the United States, Sofinnova, McDermott Will & Emery, BNP Paribas, NSL, Association of British HealthTech Industries, Patient, Bristol Myers Squibb, Microsoft, HTFC, Ipsen, Communication, International Organization for Migration (IOM) Mission in Ukraine, Rothschild, Solution, Stifel, Amgen, China Investment Securities, France Biotech, Digital, Health, Weapon, Pharmaceutical industry, Biotechnology, Ferring, Immune electron microscopy, Euronext, Medtech, Organon

The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October 13 and 14, 2022 in Paris

Key Points: 
  • The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October 13 and 14, 2022 in Paris
    The issuer is solely responsible for the content of this announcement.
  • Paris, September 6, 2022, the HealthTech Innovation Days (HTID) event, organized by the HealthTech For Care (HTFC) endowment fund, is launching for the first time a pitch competition for European healthcare companies committed to patients.
  • The purpose is to offer these companies the opportunity to present their solutions to healthcare experts and investors.
  • The winner will receive the "HealthTech For Care innovation award, which goes along with privileged connections with HTFC sponsors, visibility through dedicated communication and free access to the 5th edition of the HealthTech Innovation Days (HTID) event.

Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs

Retrieved on: 
Tuesday, September 6, 2022
EMA, Technology, Associate, Lists of people executed in the United States, Time, Vaccine, OGTR, Culture, OMICS Publishing Group, Government, Office of the Gene Technology Regulator, Investment, AU, FDA, GMO, CRO, Medidata Solutions, Knowledge, Acquisition, IBM, Drug development, Review, Frost & Sullivan, Fine chemical, Medicine, Pharmaceutical industry, Oracle

SYDNEY, AU, Sept 6, 2022 - (ACN Newswire) - Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies.

Key Points: 
  • SYDNEY, AU, Sept 6, 2022 - (ACN Newswire) - Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies.
  • The combined Avance Clinical Australia, New Zealand, and North American operations deliver a unique GlobalReady drug development model for biotechs.
  • This strong relationship made C3 Research Associates a natural acquisition choice for Avance Clinical's expansion plans into North America.
  • Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to later phase clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC

Retrieved on: 
Monday, September 5, 2022
Technology, Cancer, Lists of people executed in the United States, Ownership, Incidence, ESMO, Investment, GlobalData, Leadership, Cros, Clinical trial, Growth, Drug development, CRO, Fine chemical, Asia-Pacific

Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.

Key Points: 
  • Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.
  • In the APAC region, the proportion of oncology trials doubled during 2017-2021.
  • In China, the growth in oncology trials was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immune-oncology, and leadership in cell therapy."
  • Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases.

APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report

Retrieved on: 
Friday, September 2, 2022
Technology, NHC, Lists of people executed in the United States, Government, Ownership, Infection, National Medical Products Administration, Degenerative disease, Asia-Pacific, Investment, NMPA, GlobalData, Cros, Plasma protein binding, Clinical trial, National Health Commission, Growth, Drug development, CNS, CRO, Fine chemical, Pharmaceutical industry

The report was prepared by GlobalData and confirms that "the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period."

Key Points: 
  • The report was prepared by GlobalData and confirms that "the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period."
  • In addition, the GlobalData research found that all phases of clinical trials in the region registered higher growth than both the US and the EU5.
  • According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes.
  • It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas.

Ganymed Robotics Appoints Michel Therin and Mike Lobinsky on its Board of Directors

Retrieved on: 
Thursday, September 1, 2022
Software, Radiology, Hardware, Data Management, Technology, Medical Devices, Health Technology, Surgery, Cardiology, Biotechnology, Audio, Video, Other Technology, Health, EOS, Wilco, CEO, Technology, Organizational founder, Research, Lists of people executed in the United States, Artificial intelligence, Smith, Robotics, EOS imaging, Judgement, Board, Director, Intelligence, Elective surgery, Corindus Vascular Robotics, Leadership, Maggot therapy, Independent Board for Presbyterian Foreign Missions, BAE Systems Electronic Systems, General surgery, News, Algorithm, Stryker, Siemens Healthineers, Medtronic, Efficiency, Advanced Therapy Medicinal Product, Industry, Acquisition, Ministry of Education (Malaysia), Patient, Management, Medical device, 3D printing, Ganymed, Covidien

Ganymed Robotics , a developer of computer vision algorithms and robotics technologies for orthopedic surgeons, announced it has appointed Michel Therin as Chairman of the Board of Directors and Mike Lobinsky as Independent Board Member.

Key Points: 
  • Ganymed Robotics , a developer of computer vision algorithms and robotics technologies for orthopedic surgeons, announced it has appointed Michel Therin as Chairman of the Board of Directors and Mike Lobinsky as Independent Board Member.
  • Aside of its role as Chairman of Ganymed, Michel also serves as a Member of the Board of Directors of Tissium, Keranova, SafeHeal, Affluent Medical and Betaglue Technologies.
  • Mike Lobinsky is an accomplished medical technology executive with more than 20 years of experience in the orthopedics and surgical robotics industry.
  • Sophie Cahen, CEO and Cofounder of Ganymed Robotics, said: The arrival of Michel and Mike on our Board is terrific news as we are expanding our technology platform and preparing for commercialization.

Interim Results for the Six Months Period Ended June 30, 2022

Retrieved on: 
Thursday, September 1, 2022
Transfer, COVID-19, Piracy, Congestion, Battle of Calcasieu Pass, Insurance, Seal, Life expectancy, Time, EU taxonomy for sustainable activities, Lists of people executed in the United States, Ageing, Coral, Sale, Accident, Maintenance, TTF, Pressure, Depreciation, Golar LNG, Increment, Company, JKM, Compliance, Machine, TS Empire State VI, Knowledge, Risk, EPS, Industry, Environment, Mission statement, Review, Ice, Reinsurance, Health insurance, Airline, Security (finance), Natural gas, Audit, Industrial gas, Risk management, Successor, LNG

Administrative expenses for 1H 2022 totaled $8.1 million consisting of a combination of third-party vessel management expenses and corporate overheads.

Key Points: 
  • Administrative expenses for 1H 2022 totaled $8.1 million consisting of a combination of third-party vessel management expenses and corporate overheads.
  • In June 2022, one of our vessels entered the spot market where she continued to trade over the summer months.
  • The vessel subsequently secured a highly attractive 12-month charter rate at around $140,000 per day commencing early September 2022.
  • Another vessel will conclude her 12-month charter in October 2022, positioning her well to secure attractive new business ahead of the winter months.

Black Diamond Group Limited releases inaugural Corporate Responsibility Report

Retrieved on: 
Thursday, September 1, 2022
Diamond, MSS, Workforce, Corporation, CEO, Safety, Chief executive officer, Sustainability Accounting Standards Board, Lung compliance, Program, Ethics, MPA, BDI, WFS, TRIF, Business ethics, Health, TSX, Education, Fatality, Goal, Black Diamond, Report, Sustainability accounting, GLOBE, Transparency, EMP, Company, Compliance, Equifax Workforce Solutions, Lists of people executed in the United States, Industry, Schiavi di Abruzzo, Travel, Risk management, Audit

CALGARY, Alberta, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (Black Diamond or the "Company) (TSX: BDI), a leading provider of space rental and workforce accommodation, today released its inaugural Corporate Responsibility Report.

Key Points: 
  • CALGARY, Alberta, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (Black Diamond or the "Company) (TSX: BDI), a leading provider of space rental and workforce accommodation, today released its inaugural Corporate Responsibility Report.
  • We are excited to announce the launch of Black Diamond Groups first Corporate Responsibility Report, states Trevor Haynes, Chairman & CEO of Black Diamond Group.
  • Black Diamonds Corporate Responsibility Report is guided by The Sustainability Accounting Standards Board, or SASB, Standards.
  • To view Black Diamonds inaugural Corporate Responsibility Report, visit this link: https://www.blackdiamondgroup.com/BDG/media/media/ESG/2022-Corporate-Res...
    Black Diamond is a specialty rentals and industrial services Company with two operating business units - Modular Space Solutions (MSS) and Workforce Solutions (WFS).

Integrated DNA Technologies Launches Complete NGS Library Preparation Solution for Monkeypox

Retrieved on: 
Tuesday, August 30, 2022
Science, Other Science, Biotechnology, Research, General Health, Health, Infectious Diseases, Other Health, Monkeypox virus, ISO, Technology, Integrated DNA Technologies, Synthetic biology, Cancer, RNA, Program, Research, Arizona State University, Agriculture, YouTube, NGS, Solution, Lists of people executed in the United States, RNA interference, World, Infection, Pressure, LinkedIn, DNA, Workflow, Real-time, Library, Multimedia, Public health emergency, Public Health Emergency of International Concern, Triangle Park (Quezon City), GMP, PCR, Monkeypox, Instagram, CRISPR, ITRS, Twitter, Integration, RUO, Face, IDT, Genomics, Industry, Omicron, World Health Organization, Pharmaceutical industry, Online shopping, Vaccine, Facebook, Delta

Committed to providing quality products to researchers working on the cutting edge of scientific discovery, Integrated DNA Technologies' newly launched xGen Monkeypox Virus Amplicon Panel is a complete next generation sequencing (NGS) library preparation solution that supports the genotyping of MPXV within a sample.

Key Points: 
  • Committed to providing quality products to researchers working on the cutting edge of scientific discovery, Integrated DNA Technologies' newly launched xGen Monkeypox Virus Amplicon Panel is a complete next generation sequencing (NGS) library preparation solution that supports the genotyping of MPXV within a sample.
  • (Photo: Business Wire)
    The xGen Monkeypox Virus Amplicon Panel is a complete NGS library preparation solution that supports the genotyping of MPXV within a sample.
  • IDT tested the panel with commercially available monkeypox DNA and demonstrated coverage of positions 6760190,905 (inverted-terminal repeats (ITRs) not included).
  • In addition to releasing its monkeypox virus NGS panel, IDT also is offering custom and pre-designed qPCR solutions for monkeypox research needs.

Iantrek Raises $23M Series B Financing to Advance Next Generation Ophthalmic Micro-Interventional Technologies

Retrieved on: 
Tuesday, August 30, 2022
Icahn School of Medicine at Mount Sinai, CEO, Technology, Ginger, Ivanti, Lists of people executed in the United States, American Academy, EEG microstates, Severe cognitive impairment, Board, CFA, LinkedIn, IOP, Mount Sinai, Investment, Glaucoma, GLOBE, MIGS, Board of directors, CAGR, FDA, American Academy of Ophthalmology, Marketing, Industry, Acquisition, General partnership, Patient, Medical device, Medicine, Ophthalmology

WHITE PLAINS, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical device company founded by ophthalmic innovator Dr. Sean Ianchulev, announced the closing of a $23M Series B financing.

Key Points: 
  • WHITE PLAINS, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical device company founded by ophthalmic innovator Dr. Sean Ianchulev, announced the closing of a $23M Series B financing.
  • Iantrek is the only MIGS company with FDA-registered technologies designed to address both natural aqueous outflow pathways, trabecular and suprachoroidal.
  • We are grateful to have a world-class syndicate of investors supporting our efforts to advance these new technologies.
  • With two commercial ready MIGS platforms, Iantrek is uniquely positioned to transform the horizon of micro-interventional ophthalmic surgery.

ALR Technologies Announces Update on the GluCurve Pet CGM Distribution and Commercialization

Retrieved on: 
Monday, August 29, 2022
Partnership, Conditional sentence, Human, Program, Legislation, Form 10-K, Lists of people executed in the United States, Corporate action, Consumer Electronics Show, Cat, HIPAA, Glucose, Memory, Risk, Dog, Table, Health, Diabetes, Data management, SEC, Veterinary medicine, Infection, PETS, Animal, GLOBE, VMX, Insulin, CGM, Intention, Publication, Company, FDA, News, Electronics, Form, Annual report, OTCQB, Forward-looking statement, Marketing, Airline, Medical imaging, Pharmaceutical industry, Sensor

Furthermore, the Company has placed its first Purchase Order (PO) for the GluCurve Pet CGM hardware with delivery scheduled for October.

Key Points: 
  • Furthermore, the Company has placed its first Purchase Order (PO) for the GluCurve Pet CGM hardware with delivery scheduled for October.
  • The GluCurve Pet CGM is a Continuous Glucose Monitoring Systems for diabetic cats and dogs, consisting of an Applicator, Sensor, Transmitter, GluCurve App, and Veterinary Web Portal.
  • The GluCurve Pet CGM measures glucose levels every 3 minutes for a total of 480 readings each day, for up to 14 days.
  • Ltd. is controlled by ALR Technologies Inc., a Company with its shares traded on the OTCQB under the symbol ALRT.